Dapagliflozin as an oral antihyperglycemic agent in the management of diabetes mellitus in patients with liver cirrhosis

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 4

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

HTML

165

Figures (1-1)

Tables (1-5)

Sum=201

Publishing Process of This Article

Item

Count

Browse

Download

Sum=16

Dec 20, 2024 (publication date) through Nov 6, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Experimental Medicine

ISSN

2220-315x

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Clinical Trials Study

World J Exp Med. Dec 20, 2024; 14(4): 95272
Published online Dec 20, 2024. doi: 10.5493/wjem.v14.i4.95272

Figure 1 Diuretic dose change in the studied groups.

Citation: Seif El-Din Z, Afify M, Zayed E, Elsabaawy D, Tharwa ES, Elsharawy A, Abdelsameea E, Rady MA. Dapagliflozin as an oral antihyperglycemic agent in the management of diabetes mellitus in patients with liver cirrhosis. World J Exp Med 2024; 14(4): 95272
URL: https://www.wjgnet.com/2220-315x/full/v14/i4/95272.htm
DOI: https://dx.doi.org/10.5493/wjem.v14.i4.95272